Abraham Scaria

Abraham Scaria

Company: Beacon Therapeutics

Job title: Chief Scientific Officer

Bio:

Dr. Scaria has more than 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. For much of his career, Dr. Scaria has specialized in viral gene delivery vectors and ocular gene therapy, having served as Senior Scientific Director of Gene Therapy at Genzyme, Head of Gene Therapy Research at Sanofi-Genzyme and VP of Ophthalmology/Gene Editing at Casebia Therapeutics.

He earned his doctorate in biochemistry and molecular biology from Indiana University School of Medicine and conducted postdoctoral research at St. Louis University School of Medicine and at the University of Washington School of Medicine in Seattle. Dr. Scaria has more than 50 publications and 20 patents and currently serves on several committees for the American Society for Gene and Cell Therapy.

Seminars:

Exploring the Link Between Viral Vector Design & Quality; & Ocular Inflammation 2:50 pm

Evaluating which components of the vector stimulate inflammatory responses Can improved promoters and enhancers be developed to deliver genes effectively without triggering the immune response? Outlining the role of novel vector generation methods in reducing ocular inflammationRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.